Company Overview and News


Add 0690
to your dashboard

Headline News

Week In Review: Ping An Announces $1 Billion Fin-Tech/Healthcare VC Fund

2017-05-07 seekingalpha
Ping An Insurance Group (OTCPK:PNGAY) (OTCPK:PIAIF) (HK: 2318; SHA: 601318), China's largest insurer by market value, announced plans to launch a $1 billion international fund that will invest in fin-tech and healthcare startups. Ping An is already a player in the fin-tech area with Lufax, China's biggest peer-to-peer lending and wealth management platform. In healthcare, the company offers Ping An Good Doctor, a mobile app, which has 140 million users and is, says Ping An, the first healthcare stop for many people in China.

Uni-Bio Science Launches Best-in-Class Oral Anti-Diabetic Drug Mitiglinide Branded Bokangtai)

2017-05-04 marketwired
HONG KONG, CHINA--(Marketwired - May 4, 2017) -  Uni-Bio Science Group Limited ("Uni-Bio Science" or the "Group") (HKSE: 690) today announced that, with the exclusive global rights to manufacture and commercialize Mitiglinide acquired from Jiangsu Hansoh Pharmaceutical Co. Ltd ("Hansoh") in 2015, it is launching this new oral anti-diabetic drug (OAD) under the registered brand name (Bokangtai) today in Fujian province, subsequent to the drug being included in the 2017 NRDL.

Uni-Bio Science in Multiple Drug Co-development Deal with Beijing Sun-Novo

2016-12-01 marketwired
Extended R&D Collaboration of Oral Diabetes Drugs Promising to Meet Unmet Needs Complements the Group's R&D Capabilities and Diabetes Treatment Portfolio

Uni-Bio Science in Multiple Drug Co-development Deal with Beijing Sun-Novo

2016-12-01 business.asiaone
HONG KONG, CHINA - Media OutReach - 1 December 2016 -- Uni-Bio Science Group Limited ("Uni-Bio Science" or the "Group"; HKEx code: 690) has today announced that it has signed a multiple drug co-development deal with Beijing Sun-Novo Pharmaceutical Research Co., Ltd. ("Beijing Sun-Novo"), a China-based company engaged in research and development (R&D), manufacturing and commercialization of pharmaceutical products, to extend Uni-Bio's current R&D capabilities in small molecule drug development.

Uni-Bio Science Group Forges Strategic Alliance with LUQA

2016-11-14 marketwired
Joins Forces with LUQA in Co-promoting Drugs and Medical Devices for Treatment of Dermatological Disorders in Mainland China

Uni-Bio Science Group Forges Strategic Alliance with LUQA

2016-11-14 business.asiaone
HONG KONG, CHINA - Media OutReach - 14 November 2016 - Uni-Bio Science Group Limited ("Uni-Bio Science" or the "Group"; HKEx code: 690) has today announced that it has established a strategic partnership with Luqa Pharmaceuticals Trading (Shanghai) Co., Ltd. ("LUQA"), a China-focused specialty pharmaceutical company, to conduct co-promotion or/ and co-marketing of dermatology drugs in Mainland China, enabling the Group to immediately expand its income stream and generate cash flow.

Non-Insulin Therapies for Diabetes: GLP-1 Agonists, DPP4 Inhibitors and SGLT2 Inhibitors, 2016 - 2026

2016-11-09 prnewswire
Diabetes, considered to be the most common metabolic disorder in humans, is ranked among the top ten fatal diseases in the US. The increasing incidence, growing prevalence and the progressive nature of the disease has spurred several pharmaceutical companies to develop novel approaches / therapies to provide better treatment options for diabetic patients worldwide. While insulin supplements and insulin based therapies represent a major portion of the anti-diabetic drugs market, non-insulin therapies are first line therapies designed especially for patients suffering from type II diabetes.

Week In Review: Hepalink Invests $13 Million In Canada's OncoQuest

2016-09-18 seekingalpha
Shenzhen Hepalink Pharma (SHZ: 002399) closed a $13 million investment in OncoQuest, the oncology subsidiary of Canada's Quest PharmaTech (TSX-V: QPT) (OTC:QPTFF), giving Hepalink a 42% stake in OncoQuest (see story). OncoQuest is developing several immunotherapeutic antibodies to treat cancer. The two companies are also reported to be in talks on a $5 million JV to develop OncoQuest's products in China.

Non-Insulin Therapies for Diabetes: GLP-1 Agonists, DPP4 Inhibitors and SGLT2 Inhibitors, 2016 - 2026

2016-08-23 prnewswire
Diabetes, considered to be the most common metabolic disorder in humans, is ranked among the top ten fatal diseases in the US. The increasing incidence, growing prevalence and the progressive nature of the disease has spurred several pharmaceutical companies to develop novel approaches / therapies to provide better treatment options for diabetic patients worldwide. While insulin supplements and insulin based therapies represent a major portion of the anti-diabetic drugs market, non-insulin therapies are first line therapies designed especially for patients suffering from type II diabetes.

Week In Review: China Bridge Capital Announces $1.5 Billion Precision Medicine Fund

2016-07-17 seekingalpha
China Bridge Capital, a Beijing financial services firm, invested $45 million in iCarbonX, the big data/AI healthcare start-up that raised $155 million in a Series A at a $1 billion valuation earlier this year. iCarbonX was founded by Jun Wang, formerly CEO of BGI, China's giant gene sequencing company. China Bridge also plans to raise $1.5 billion for an investment fund that acquires precision healthcare assets, a focus area for iCarbonX.